CN115175911A - 用于治疗认知损害的苯二氮䓬衍生物、组合物和方法 - Google Patents

用于治疗认知损害的苯二氮䓬衍生物、组合物和方法 Download PDF

Info

Publication number
CN115175911A
CN115175911A CN202080096714.0A CN202080096714A CN115175911A CN 115175911 A CN115175911 A CN 115175911A CN 202080096714 A CN202080096714 A CN 202080096714A CN 115175911 A CN115175911 A CN 115175911A
Authority
CN
China
Prior art keywords
cognitive impairment
compound
gaba
disorder
cognitive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080096714.0A
Other languages
English (en)
Chinese (zh)
Inventor
B·梅科嫩
J·A·布特拉
黄建星
H·帕特尔
Q·江
R·J·赫尔
E·E·弗里曼
N·J·梅休
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agenebio Inc
Original Assignee
Agenebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenebio Inc filed Critical Agenebio Inc
Publication of CN115175911A publication Critical patent/CN115175911A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN202080096714.0A 2019-12-19 2020-12-18 用于治疗认知损害的苯二氮䓬衍生物、组合物和方法 Pending CN115175911A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962950886P 2019-12-19 2019-12-19
US62/950,886 2019-12-19
PCT/US2020/066182 WO2021127543A1 (en) 2019-12-19 2020-12-18 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Publications (1)

Publication Number Publication Date
CN115175911A true CN115175911A (zh) 2022-10-11

Family

ID=76478828

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080096714.0A Pending CN115175911A (zh) 2019-12-19 2020-12-18 用于治疗认知损害的苯二氮䓬衍生物、组合物和方法

Country Status (8)

Country Link
US (1) US20230098667A1 (cg-RX-API-DMAC7.html)
EP (1) EP4077333A4 (cg-RX-API-DMAC7.html)
JP (2) JP7737721B2 (cg-RX-API-DMAC7.html)
CN (1) CN115175911A (cg-RX-API-DMAC7.html)
AU (1) AU2020405233A1 (cg-RX-API-DMAC7.html)
IL (1) IL294031A (cg-RX-API-DMAC7.html)
MX (1) MX2022007725A (cg-RX-API-DMAC7.html)
WO (1) WO2021127543A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180170941A1 (en) * 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US12039851B2 (en) * 2019-05-23 2024-07-16 Lifeguard Ai, Inc. System and a method for surveilling swimmers
WO2024023268A1 (en) 2022-07-29 2024-02-01 F. Hoffmann-La Roche Ag Characterisation of neurological dysfunction
EP4572852A1 (en) * 2022-08-19 2025-06-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108026107A (zh) * 2015-06-19 2018-05-11 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
US20180170941A1 (en) * 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4032889B1 (en) * 2013-12-20 2026-05-06 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
AU2019288382B2 (en) * 2018-06-19 2024-07-25 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP4178961A4 (en) * 2020-07-10 2024-07-31 Agenebio, Inc. POLYMORPHS OF A GABAA APLHA5 AGONIST AND METHODS OF USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT
JP7867287B2 (ja) * 2020-07-10 2026-05-29 エージンバイオ, インコーポレイテッド Gabaaアルファ5アゴニストおよびsv2a阻害剤の組合せ物ならびに認知障害の処置において使用する方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108026107A (zh) * 2015-06-19 2018-05-11 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
US20190055258A1 (en) * 2015-06-19 2019-02-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) * 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CN110382501A (zh) * 2016-12-19 2019-10-25 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物,组合物和方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUIDO ACHERMANN,等: "Discovery of the imidazo[1, 5-a][1, 2, 4]-triazolo[1, 5-d][1, 4]benzodiazepine scaffold as a novel, potent and selective GABAA a5 inverse agonist series", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》, vol. 19, no. 19, 4 August 2009 (2009-08-04), pages 5749 *

Also Published As

Publication number Publication date
MX2022007725A (es) 2022-07-19
IL294031A (en) 2022-08-01
US20230098667A1 (en) 2023-03-30
AU2020405233A1 (en) 2022-07-14
EP4077333A4 (en) 2024-01-10
EP4077333A1 (en) 2022-10-26
JP2023507569A (ja) 2023-02-24
JP2025107315A (ja) 2025-07-17
JP7737721B2 (ja) 2025-09-11
WO2021127543A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
US11142529B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US12291535B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US12528819B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20210009602A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP7737721B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
HK40077472A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40081455A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1230171B (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1254300A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1254300B (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1230170A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1230170B (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40081455

Country of ref document: HK